We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
-10.91%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$157M
(-13%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
12.82%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
41
New
5
Increased
4
Reduced
2
Closed
3
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Upstream Bio Inc
UPB
|
+$62.6M |
| 2 |
Tango Therapeutics
TNGX
|
+$49.8M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$38.6M |
| 4 |
EyePoint Inc
EYPT
|
+$24.7M |
| 5 |
RAPT Therapeutics
RAPT
|
+$20.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$56.4M |
| 2 |
Keros Therapeutics
KROS
|
+$17.1M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$7.62M |
| 4 |
AN2 Therapeutics
ANTX
|
+$1.66M |
| 5 |
Adverum Biotechnologies
ADVM
|
+$1.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$5.48B
| $105M | 10.29% |
3,670,206
| – | – |
2024 Q1
3 quarters
|
|
2
Dyne Therapeutics
DYN
$2.81B
| $62.4M | 6.1% |
2,650,150
| – | – |
2023 Q1
7 quarters
|
|
3
Xencor
XNCR
$1.74B
| $56.4M | 5.51% |
2,452,138
+25,000
| +1% | +$574K |
2024 Q3
1 quarter
|
|
4
Cogent Biosciences
COGT
$4.88B
| $54.3M | 5.31% |
6,964,375
| – | – |
2021 Q4
12 quarters
|
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $48.4M | 4.73% |
2,890,816
| – | – |
2023 Q3
5 quarters
|
|
6
Ocular Therapeutix
OCUL
$1.58B
| $45.4M | 4.44% |
5,319,148
| – | – |
2024 Q1
3 quarters
|
|
|
7
Upstream Bio Inc
UPB
$187M
| $44.9M | 4.38% |
+2,801,763
| New | +$62.6M |
2024 Q4
0 quarters
|
|
8
Abivax
ABVX
$7.68B
| $44.3M | 4.33% |
6,056,596
| – | – |
2023 Q4
4 quarters
|
|
9
Savara
SVRA
$978M
| $38M | 3.71% |
12,362,205
| – | – |
2023 Q3
5 quarters
|
|
|
10
Tango Therapeutics
TNGX
$3.74B
| $33.2M | 3.24% |
+10,736,000
| New | +$49.8M |
2024 Q4
0 quarters
|
|
|
11
Dianthus Therapeutics
DNTH
$4.18B
| $32.7M | 3.2% |
+1,501,624
| New | +$38.6M |
2024 Q4
0 quarters
|
|
12
Disc Medicine
IRON
$2.14B
| $30.9M | 3.02% |
486,957
| – | – |
2024 Q2
2 quarters
|
|
13
Mineralys Therapeutics
MLYS
$1.84B
| $30.4M | 2.97% |
2,470,265
| – | – |
2024 Q1
3 quarters
|
|
14
DELISTED
Tourmaline Bio
TRML
| $30M | 2.93% |
1,477,593
| – | – |
2023 Q4
4 quarters
|
|
15
Structure Therapeutics
GPCR
$1.56B
| $28.8M | 2.82% |
1,063,000
| – | – |
2023 Q1
7 quarters
|
|
16
Tyra Biosciences
TYRA
$1.29B
| $27.6M | 2.7% |
1,989,103
| – | – |
2021 Q4
12 quarters
|
|
|
17
EyePoint Inc
EYPT
$259M
| $26.6M | 2.6% |
3,572,335
+2,650,000
| +287% | +$24.7M |
2024 Q2
2 quarters
|
|
18
DELISTED
Cidara Therapeutics
CDTX
| $26.1M | 2.55% |
+1,005,901
| New | +$16.3M |
2024 Q4
0 quarters
|
|
19
DELISTED
Third Harmonic Bio
THRD
| $25.8M | 2.52% |
2,505,424
+90,424
| +4% | +$1.13M |
2024 Q3
1 quarter
|
|
20
DELISTED
Soleno Therapeutics
SLNO
| $24.7M | 2.42% |
550,000
| – | – |
2024 Q1
3 quarters
|
|
21
DELISTED
Astria Therapeutics
ATXS
| $24.7M | 2.41% |
2,761,861
| – | – |
2024 Q1
3 quarters
|
|
22
Fulcrum Therapeutics
FULC
$280M
| $24.7M | 2.41% |
5,250,000
| – | – |
2024 Q3
1 quarter
|
|
23
Silence Therapeutics
SLN
$558M
| $20.9M | 2.04% |
3,033,560
| – | – |
2022 Q3
9 quarters
|
|
|
24
DELISTED
RAPT Therapeutics
RAPT
| $19.8M | 1.93% |
+1,641,908
| New | +$20.9M |
2024 Q4
0 quarters
|
|
25
Amylyx Pharmaceuticals
AMLX
$3.39B
| $17.6M | 1.72% |
4,643,812
| – | – |
2024 Q3
1 quarter
|
|
Similar funds
CCMIC
TCG Crossover Management's Q4 2024 Portfolio in Review
As of Q4 2024, TCG Crossover Management held 41 positions worth $1.02B, down 13% from $1.18B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
TCG Crossover Management deployed $131M of net new capital in Q4 2024, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Upstream Bio Inc: 2,801,763 shares worth $44.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Keros Therapeutics, an estimated $17.1M trimmed.
- TCG Crossover Management's largest Q4 2024 buy was Upstream Bio Inc: 2,801,763 shares worth $44.9M.
- TCG Crossover Management added most to EyePoint Inc in Q4 2024, an estimated $24.7M increase.
- TCG Crossover Management's biggest Q4 2024 reduction was Keros Therapeutics, cutting an estimated $17.1M.
- TCG Crossover Management fully exited Edgewise Therapeutics in Q4 2024, selling an estimated $56.4M.
- TCG Crossover Management's ten largest holdings make up 52% of its $1.02B portfolio in Q4 2024.
- TCG Crossover Management opened 5 new positions and closed 3 in Q4 2024.
- TCG Crossover Management's portfolio value fell 13% quarter-over-quarter to $1.02B.
Based on TCG Crossover Management's 13F filing for Q4 2024, filed 14 Feb 2025.